Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733387 | 0.91 | CCR4 (0.52) | CCR4 | |
| SCHEMBL1733274 | 0.90 | CCR4 (0.52) | CCR4EDNRA | |
| SCHEMBL1733421 | 0.88 | CCR4 (0.56) | CCR4 | |
| SCHEMBL4699972 | 0.86 | CCR4 (0.41) | CCR4 | |
| SCHEMBL4699938 | 0.86 | CCR4 (0.39) | CCR4 | |
| SCHEMBL1731807 | 0.86 | CCR4 (0.42) | CCR4 | |
| SCHEMBL4704190 | 0.85 | CCR4 (0.41) | CCR4 | |
| SCHEMBL5907751 | 0.82 | CCR4 (0.50) | CCR4 | |
| SCHEMBL6180260 | 0.81 | CCR4 (0.52) | CCR4EDNRA | |
| SCHEMBL4704825 | 0.81 | CCR4 (0.44) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467976-B1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-11-23 | — | — | EP | disclosed |
| WO-2011081310-A3 | PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME | 한국기초과학지원연구원 (KR) | 2011-10-27 | — | — | WO | disclosed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | disclosed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| EP-1633729-B1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007035154-A1 | NOVEL N-PYRAZINIL-PHENYLSULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF ASTHMA | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1633729-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| WO-2004108692-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| EP-1467976-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059893-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | CCL11, CCL2, CCR2 | CCR4 20/4885EDNRA 257/4885 |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | CCL11, CCL2, CCR2 | CCR4 20/4885EDNRA 257/4885 |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | CCR4, CCR1, CCR3 | CCR4 1/4885EDNRA 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.